Imagine staring down one of the deadliest cancers out there, where survival odds feel stacked against you from the start—yet in 2025, a wave of real hope crashed through the barriers, proving that teamwork and innovation can change the game for pancreatic cancer patients. If you've ever wondered how far we've come in battling this tough foe, stick around, because this year was packed with breakthroughs that could redefine the future.
Anna Berkenblit, the Chief Scientific and Medical Officer at the Pancreatic Cancer Action Network (PanCAN), recently posted this inspiring update on LinkedIn (https://www.linkedin.com/pulse/pancreatic-cancer-2025-year-progress-partnership-anna-berkenblit-z4ybe/?trackingId=ANBpfvsqg9i%2FWDrtKP7aaQ%3D%3D). Let's dive into her reflections on a year that blended hard-fought wins with some sobering hurdles.
As we wrap up 2025, it's undeniable: the battle against pancreatic cancer gained serious ground this year. This disease is still among the toughest to tackle—it's the only major cancer type where the five-year survival rate hovers under 20%, which hits hard for patients and families. But don't lose heart; momentum built steadily in key areas like cutting-edge research, fresh clinical approaches, and stronger voices from patient advocates. Think about it: strides in spotting the cancer early, tailoring treatments to individual genetics (that's precision medicine, for those new to the term—it means customizing therapies based on a person's unique biology), teaming up across medical specialties, and using big data to spark discoveries. All this shows what happens when scientists, doctors, collaborators, and those living with the disease unite with real drive and common goals. Sure, we hit roadblocks, like shaky federal funding for research, but there's plenty to cheer about too.
For years, lawmakers from both sides of the aisle have backed big investments in science on Capitol Hill—it's like the glue holding our progress together. But 2025 threw curveballs with talk of budget slashes, funding holds, and even a government shutdown that put the brakes on vital work, sparking fears we'd lose talented young scientists to other fields. Our community didn't sit idle; we rallied, raised our voices loud and clear, and pushed Congress to renew that solid, cross-party commitment to cancer research in their latest budget plans. Now, the big push is getting those bills over the finish line so life-changing studies can keep rolling without a hitch. And here's where it gets controversial: some argue that tying research funds to political whims is a risky game—do you think stable, long-term funding should be a non-negotiable right for diseases like this?
Even with those ups and downs, 2025 shone bright with the launch of PanCAN's Research Recovery Grants (https://pancan.org/press-releases/pancan-announces-new-grants-providing-urgent-bridge-funding-for-pancreatic-cancer-researchers-who-are-facing-delays-or-cuts-in-federal-funding/). These are like emergency lifelines for top-notch projects threatened by funding gaps. In simple terms, they keep promising experiments alive when federal support wavers, preventing a total stall in momentum—especially since many labs and universities are still navigating uncertain grant landscapes. By backing the most impactful studies, these grants not only preserve this year's gains but also pave the way for bigger leaps in 2026. It's a smart move that cements PanCAN's spot as a major player in funding pancreatic cancer science.
'PanCAN’s unwavering commitment to identifying new resources for research and advocacy will ensure that progress continues uninterrupted. This is exactly why their comprehensive approach to fighting the world’s toughest cancer is so vital.' — Howard Crawford, PhD, Henry Ford Health System and PanCAN Scientific and Medical Advisory Board Member.
Breakthrough Science and Research Milestones
For ages, the RAS gene—mutated in over 90% of pancreatic cancers and often called 'undruggable' because it was so hard to target with meds—seemed like an impossible puzzle. But 2025 flipped the script, making it finally within reach for drug developers. A huge leap came with the RASOLUTE 302 trial (https://clinicaltrials.gov/study/NCT06625320), the most advanced study yet, which just wrapped up recruiting participants. This phase 3 trial is putting Revolution Medicines' experimental drug, daraxonrasib (RMC-6236) (https://www.linkedin.com/company/revolution-medicines/), to the test against standard chemotherapy in folks with spreading pancreatic cancer. We're all on pins and needles for the 2026 results, which could show if this pan-RAS inhibitor—unlike earlier ones that only hit a tiny fraction of mutations—can broadly transform how we fight this beast. To break it down for beginners: RAS is like a faulty switch in cells that tells cancer to grow wildly; drugs like this aim to flip it off for more patients.
The buzz around this got even louder when the FDA handed Revolution Medicines a Priority Review Voucher for daraxonrasib—a rare honor that screams 'this is urgent' for unmet needs in pancreatic cancer treatments. It's a nod to how desperately we need new options.
Daraxonrasib could be the trailblazer for a whole lineup of RAS-focused therapies. Labs and clinics are buzzing with other ideas too, like combos that tackle resistance when using a single RAS blocker, all with the aim of boosting survival rates. And this is the part most people miss: while these advances sound revolutionary, critics worry about access—will these pricey new drugs reach everyone, or just a privileged few? What do you think—should cost be a barrier in life-or-death research?
Personalized, data-fueled research picked up speed in 2025, and PanCAN's SPARK platform (https://pancan.org/spark/) is at the heart of it. For newcomers, SPARK is like a supercharged database that pulls together real patient info—from medical records and DNA to scans, tissue samples, and even how patients feel day-to-day. This setup lets researchers sift through it collaboratively and quickly, spotting trends in how the cancer spreads or reacts to drugs that traditional methods might miss.
One standout collab was PanCAN teaming up with Acurion, Inc. to supercharge SPARK's digital pathology slides with their AI tool, OncoGaze (https://pancan.org/press-releases/the-pancreatic-cancer-action-network-announces-partnership-with-acurion-to-accelerate-pancreatic-cancer-diagnostics-using-ai-and-real-world-patient-data/). Imagine AI as a tireless detective scanning images for subtle clues, like tumor shapes or patterns. Their goal? Unearthing useful biomarkers, such as homologous recombination deficiency (HRD)—a DNA repair glitch that makes tumors vulnerable to certain therapies. Spotting HRD via AI on slides could speed up picking the best treatments and cut costs, giving patients stronger starting options right away. For example, if HRD is flagged early, docs might jump to PARP inhibitors, which are already game-changers for other cancers.
'The fusion of SPARK’s real-world data with emerging AI technologies represents a unique opportunity to accelerate innovation in pancreatic cancer care. We are uncovering insights with the goals of more precise diagnoses, better treatment decisions, and ultimately, a future in which all patients with pancreatic cancer will thrive.' — Sudheer Doss Ph.D., PanCAN’s Chief Business Officer
Momentum in Early Detection
Catching pancreatic cancer before it spreads is our golden ticket to better survival, and 2025 delivered solid steps forward. PanCAN's Early Detection Initiative (EDI) (https://pancan.org/research/early-detection-initiative/) kept pushing boundaries, exploring links between blood sugar shifts—like those in new diabetes cases—and pancreatic cancer risks. They're also checking if routine scans for fresh diabetes diagnoses could uncover hidden tumors sooner. A major win? Wrapping up enrollment for over 8,800 people (https://pancan.org/news/pancans-early-detection-initiative-reaches-important-milestone/), setting the stage for ongoing tracking and analysis. Get ready for one-year check-in results in 2026—they might reveal patterns that save lives.
A New Treatment Option for Pancreatic Neuroendocrine Tumors
Big news for a rarer corner of pancreatic cancer: the FDA greenlit CABOMETYX (cabozantinib) for pancreatic neuroendocrine tumors (PNETs) (https://pancan.org/news/fda-approves-new-treatment-for-pnets-what-you-need-to-know/). This multi-target drug blocks enzymes that fuel tumor growth and is for patients whose cancer grew despite earlier treatments. PNETs make up just a small slice of cases but are still brutal; this approval widens the toolbox, inching us toward options for every subtype. It's a reminder that even niche advances can ripple out to the whole field.
Research Progress Highlighted at American Society of Clinical Oncology (ASCO) 2025
The ASCO Annual Meeting (https://www.linkedin.com/company/american-society-of-clinical-oncology/posts/?feedView=all) was a hotspot for pancreatic cancer updates this year. A standout was data from a phase 3 trial on Novocure’s Tumor Treating Fields (TTFields) for advanced, inoperable cases. TTFields uses low-intensity electric fields to disrupt cancer cell division—think of it as zapping tumors without invasive surgery. Paired with chemo (gemcitabine plus nab-paclitaxel), it edged out chemo alone in survival without spread, less pain, and overall lifespan. Already a go-to for brain and lung cancers, TTFields could slot into pancreatic care with more tweaks—exciting, right?
Other talks covered biomarker-guided therapies (matching drugs to tumor markers) and inequities in spotting cancer early, getting top care, or joining trials. These spotlights hammered home pancreatic cancer's tricky nature while showcasing the wide net of ongoing studies tackling it from all angles.
Scientific Summit 2025: Together, We Are Catalysts for Change
PanCAN's yearly Scientific Summit (https://pancan.org/news/research-spotlight/research-spotlight-building-momentum-and-hope-reflections-on-pancans-2025-scientific-summit-and-aacr-pancreatic-cancer-conference/) gathered top minds and up-and-comers for two intense days of idea-sharing. It was a breeding ground for fresh thinking, from how immune therapies work (or don't) to what drives cancer spread, tweaks in the tumor's surrounding environment, and smarter early-spotting tech. The event highlighted our community's power and the must-have of cross-field teamwork to speed things up. Spotlighting young researchers? That's investing in tomorrow's breakthroughs—vital when funding squeezes hit hardest.
Support for Patients and Families
Beyond the lab, 2025 stepped up for those facing the disease head-on. PanCAN joined forces with Smart Patients to launch an online hub (https://pancan.org/press-releases/pancreatic-cancer-action-network-collaborates-with-smart-patients-to-launch-online-community-for-pancreatic-cancer-patients-and-caregivers/), where patients and loved ones can chat live, swap stories, and grab tips. It's like a virtual support circle, aligning with PanCAN's pledge to arm folks with knowledge and camaraderie every step of the way—from diagnosis to beyond.
PanCAN Research Grants
Facing federal funding woes, PanCAN rolled out fresh grants (https://pancan.org/press-releases/pancan-invests-in-new-research-grants-amid-federal-funding-challenges-advancing-innovation-and-hope-for-patients-with-pancreatic-cancer/) for ideas spanning early alerts, cancer biology basics, fair access to care, and hot new drugs. These fuel bold projects that could rewrite the rules and kick off PanCAN's yearly research push, with more funding rounds coming soon.
Throughout the year's research spotlights, patterns popped: data mash-ups driving insights, spotlighting care gaps, young talents shining, and partnerships across borders fueling wins. It's a vibrant scene, laser-focused on better lives for everyone affected.
Looking Ahead
Pancreatic cancer still ranks as the third top cancer killer in the U.S., but 2025 proved we're gaining traction. From AI sharpening diagnostics to custom meds, early hunts, trial tweaks, support nets, and funding fights, it was a year of drive and direction. Every find, alliance, and effort nudges us toward quicker catches, sharper treatments, and brighter tomorrows.
PanCAN's all-in on lobbying for steady federal bucks so researchers keep at it. As 2025 fades, the vibe is upbeat: science is speeding up, turning lab wins into real survival stories. From bolstering research bases to growing patient aids and sparking collabs, we're charging ahead with grit and optimism.
PanCAN's mission? Drive gains against pancreatic cancer now and forever. We rally the community, challenge limits, aiming for a world where beating this is standard. Hand in hand, we're building one with routine early checks, kinder treatments, and thriving survivors.
A huge shoutout to PanCAN's amazing backers—donors, helpers, champions—you're the heartbeat making this possible.
But let's talk controversy: With all this progress, why do survival rates lag so far behind other cancers? Is it underfunding, or something deeper in the system? Share your thoughts in the comments—do you agree we're on the cusp of a breakthrough, or is more urgency needed? I'd love to hear your take!
More posts featuring Anna Berkenblit. (https://oncodaily.com/tag/anna-berkenblit)
